Nindanib 150mg capsule (Nintedanib)

Nindanib 150 Soft Gelatin Capsule is used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer. It works by targeting certain pathways involved in the growth and progression of these diseases and helps to stop or slow the spread of cancer cells.

Category:

Description

Nindanib (Nintedanib)

Generic Name

Nintedanib

Drug Class

Tyrosine kinase inhibitor (antifibrotic agent)

Uses

Nintedanib is prescribed for adults to:

  • Treat Idiopathic Pulmonary Fibrosis (IPF).
  • Treat progressive fibrosing Interstitial Lung Disease.
  • Slow lung function decline in Systemic Sclerosis-Associated Interstitial Lung Disease.

Mechanism of Action

Nintedanib blocks multiple tyrosine kinase receptors involved in fibrosis and tissue scarring. By inhibiting these pathways, it helps slow the progression of lung fibrosis and preserves lung function.

Dosage

  • Common adult dose: 150 mg twice daily, approximately 12 hours apart.
  • Capsules should be taken with food and swallowed whole.
  • Dose adjustments may be required if side effects occur.

Common Side Effects

  • Diarrhea
  • Nausea
  • Vomiting
  • Abdominal pain
  • Decreased appetite
  • Weight loss
  • Headache
  • Elevated liver enzymes
  • High blood pressure

Serious Warnings

  • Liver toxicity
  • Increased risk of bleeding
  • Risk of heart attack or stroke
  • Gastrointestinal perforation (rare but serious)
  • Harm to an unborn baby; pregnancy should be avoided during treatment.

Precautions

  • Regular liver function monitoring is recommended.
  • Inform your doctor if you have liver disease, bleeding disorders, cardiovascular disease, or are taking blood thinners.
  • Avoid use during pregnancy and breastfeeding unless specifically advised by a physician.

Storage

Store at room temperature, away from excessive heat and moisture, and keep out of reach of children.

Reviews

There are no reviews yet.

Be the first to review “Nindanib 150mg capsule (Nintedanib)”

Your email address will not be published. Required fields are marked *